ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for atrial fibrillation and other cardiovascular diseases, announced today that Dr. Michael Bristow, President and Chief Executive Officer, will present “The Changing Paradigms in Drug Development” at conference session “Joint Symposium of the Heart Failure Society and the American College of Cardiology II: Heart Failure Care in the Era of Health Care Reform” at the American College of Cardiology 62 nd Annual Scientific Sessions & Expo, being held March 9-11, 2013 in San Francisco, California. The conference session is scheduled on Sunday, March 10, 2013, from 12:30pm – 1:45pm Pacific. More information about the conference is available at: www.accscientificsession.org. About ARCA biopharma ARCA biopharma is dedicated to developing genetically-targeted therapies for cardiovascular diseases. The Company's lead product candidate is Gencaro TM (bucindolol hydrochloride), an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for the prevention of atrial fibrillation. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential to be the first genetically-targeted atrial fibrillation prevention treatment. For more information please visit www.arcabiopharma.com. Safe Harbor Statement This press release and the associated presentation may contain "forward-looking statements" for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding genetic variations to predict individual patient response to Gencaro, Gencaro’s potential to treat atrial fibrillation, future treatment options for patients with atrial fibrillation and the potential for Gencaro to be the first genetically-targeted atrial fibrillation prevention treatment. Such statements are based on management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the risks and uncertainties associated with: the Company's financial resources and whether they will be sufficient to meet the Company's business objectives and operational requirements; results of earlier clinical trials may not be confirmed in future trials, the protection and market exclusivity provided by the Company’s intellectual property; risks related to the drug discovery and the regulatory approval process; and the impact of competitive products and technological. These and other factors are identified and described in more detail in ARCA’s filings with the SEC, including without limitation the Company’s annual report on Form 10-K for the year ended December 31, 2011 and subsequent filings. The Company disclaims any intent or obligation to update these forward-looking statements.